🇺🇸 FDA
Pipeline program

GTS-21

IRB201500393

Phase 2 small_molecule terminated

Quick answer

GTS-21 for Tobacco Use Disorder is a Phase 2 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
Tobacco Use Disorder
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials